MARKET

STRO

STRO

Sutro Biopharma
NASDAQ
23.78
-1.09
-4.38%
After Hours: 23.49 -0.29 -1.22% 19:14 04/02 EDT
OPEN
24.11
PREV CLOSE
24.87
HIGH
25.39
LOW
23.65
VOLUME
126.59K
TURNOVER
--
52 WEEK HIGH
26.54
52 WEEK LOW
5.23
MARKET CAP
393.97M
P/E (TTM)
-1.0575
1D
5D
1M
3M
1Y
5Y
1D
Sutro Biopharma Enters Sales Agreement With TD Securities; Co. May Offer & Sell Shares Of Common Stock Of Up To $100M
Benzinga · 3d ago
SUTRO BIOPHARMA: ENTERS SALES AGREEMENT, MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $100 MLN - SEC FILING
Reuters · 3d ago
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?
NASDAQ · 4d ago
Weekly Report: what happened at STRO last week (0323-0327)?
Weekly Report · 6d ago
Sutro Biopharma Is Maintained at Buy by Deutsche Bank
Dow Jones · 03/25 16:53
Deutsche Bank Maintains Buy on Sutro Biopharma, Raises Price Target to $55
Benzinga · 03/25 16:43
Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank
TipRanks · 03/25 12:51
SUTRO BIOPHARMA INC. <STRO.O>: DEUTSCHE BANK RAISES TARGET PRICE TO $55 FROM $51
Reuters · 03/25 11:05
More
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Webull offers Sutro Biopharma Inc stock information, including NASDAQ: STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.